416 related articles for article (PubMed ID: 22594899)
1. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
2. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
3. Current status of antiangiogenic therapies for glioblastomas.
Arrillaga-Romany I; Reardon DA; Wen PY
Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic inhibition in high-grade gliomas: past, present and future.
Jo J; Schiff D; Purow B
Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
[TBL] [Abstract][Full Text] [Related]
5. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
de Boüard S; Guillamo JS
Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
8. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
Simpson L; Galanis E
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
[TBL] [Abstract][Full Text] [Related]
9. The role of avastin in the management of recurrent glioblastoma.
Sweet JA; Feinberg ML; Sherman JH
Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic Therapy of High-Grade Gliomas.
Jo J; Wen PY
Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
[TBL] [Abstract][Full Text] [Related]
13. [Topics for antiangiogenic therapy for glioblastoma].
Takano S; Matsumura A
No Shinkei Geka; 2012 Jun; 40(6):481-502. PubMed ID: 22647508
[No Abstract] [Full Text] [Related]
14. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
Rose SD; Aghi MK
Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
[No Abstract] [Full Text] [Related]
15. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of tumor-associated endothelial cells derived from glioblastoma multiforme.
Charalambous C; Chen TC; Hofman FM
Neurosurg Focus; 2006 Apr; 20(4):E22. PubMed ID: 16709028
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis and invasion in malignant gliomas.
Chi A; Norden AD; Wen PY
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1537-60. PubMed ID: 18020923
[TBL] [Abstract][Full Text] [Related]
19. Resistance to antiangiogenic therapies.
Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
[TBL] [Abstract][Full Text] [Related]
20. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Seystahl K; Weller M
Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
